A molecular trio in relapse and remission in multiple sclerosis

  title={A molecular trio in relapse and remission in multiple sclerosis},
  author={Lawrence Steinman},
  journal={Nature Reviews Immunology},
  • L. Steinman
  • Published 1 June 2009
  • Biology, Medicine
  • Nature Reviews Immunology
Two thirds of patients with multiple sclerosis have the relapsing-remitting form, which often progresses to more debilitating disease. Striking clinical recovery, termed remission, often follows these periodic neurological defects, termed relapses. Recent work has revealed the role of three key molecules in relapse and remission: α4β1 integrin (also known as VLA4) is an adhesion molecule that mediates T cell migration from the blood into the brain; osteopontin binds to α4β1 integrin… 

Immunology of relapse and remission in multiple sclerosis.

  • L. Steinman
  • Medicine, Biology
    Annual review of immunology
  • 2014
The most potent drug for inhibiting relapses, the humanized anti-α4 integrin antibody known as Natalizumab, blocks homing of mononuclear cells to the CNS and provides a strong foundation for understanding the pathobiology of the relapse.

Pathogenic mechanisms and experimental models of multiple sclerosis

Current therapies, lessons learned from failed clinical trials, genetic susceptibility, key cell types involved, animal models, gene expression, and biomarker information are reviewed to guide more effective treatment and management of this autoimmune disease.

The good and the bad of neuroinflammation in multiple sclerosis.

Innate immunity in progressive multiple sclerosis

The findings suggest that later stages of MS is characterized less of adaptive and innate cellular alterations in the periphery, also supported by the relative lack of efficacy of current therapies in MS directed mainly at modulating the adaptive immune defense.

The discovery of natalizumab, a potent therapeutic for multiple sclerosis

  • L. Steinman
  • Biology, Psychology
    The Journal of cell biology
  • 2012
In 1992, in a collaboration between academia and biotechnology, colleagues and I showed that α4 integrin was the critical molecule involved in the homing of immune cells into the inflamed brain.

The immuno-pathophysiology of multiple sclerosis

This review will explore the principle features of the immuno-pathology of MS, in particular of relapsing-remitting MS (RR-MS), and emerging concepts in the pathogenesis of MS in the context of known features of pathology have been highlighted.

The immunopathophysiology of multiple sclerosis.

Tissue hypoxia in autoimmune brain disease: A Columbian discovery?

The data provide undisputable evidence of hypoxic changes in the spinal cord white matter, and, importantly, pimonidazole staining correlates with disease severity, which is impressively borne out in the present studies.

Treatment of refractory epilepsy with natalizumab in a patient with multiple sclerosis. Case report

The case report suggests that inhibition of leukocyte adhesion may represent a new potential therapeutic approach in epilepsy and complement the traditional therapy with anti-epileptic drugs.

New approaches in the management of multiple sclerosis

Data from clinical trials of newer agents of potential benefit in MS are provided, with reductions in MS relapse rates and improvements in T₂ or gadolinium-enhancing lesion burdens reported from Phase III trials that include fingolimod, alemtuzumab, cladribine, and rituximab.



A controlled trial of natalizumab for relapsing multiple sclerosis.

In a placebo-controlled trial, treatment with natalizumab led to fewer inflammatory brain lesions and fewer relapses over a six-month period in patients with relapsing multiple sclerosis.

Osteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells

Osteopontin triggered recurrent relapses, promoted worsening paralysis and induced neurological deficits, including optic neuritis in models of multiple sclerosis including relapsing, progressive and multifocal experimental autoimmune encephalomyelitis.

Elevated osteopontin levels in active relapsing‐remitting multiple sclerosis

Interestingly, active relapsing‐remitting patients had higher OPN protein levels than patients without relapses, and OPN levels in primary progressive and secondary progressive MS patients were similar to healthy control levels.

Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab

  • L. Steinman
  • Medicine, Psychology
    Nature Reviews Drug Discovery
  • 2005
Three months after its expedited approval by the FDA, natalizumab was removed from the market after two cases of deadly progressive multifocal leukoencephalopathy were reported among the few thousand patients who had taken this drug in those clinical trials.

The Influence of the Proinflammatory Cytokine, Osteopontin, on Autoimmune Demyelinating Disease

Osteopontin appears to regulate T helper cell–1 (TH1)–mediated demyelinating disease, and it may offer a potential target in blocking development of progressive MS.

Nuanced roles of cytokines in three major human brain disorders.

  • L. Steinman
  • Biology, Medicine
    The Journal of clinical investigation
  • 2008
Although cytokine-modulating therapies are not currently in clinical use for the treatment ofAD, cytokines can ameliorate disease pathology in certain experimental models of AD, suggesting a potential for future therapeutic opportunities.

Osteopontin polymorphisms and disease course in multiple sclerosis

A modest trend for association with disease course was detected in patients carrying at least one wild-type 1284A allele, suggesting an effect on disease course, and patients with this genotype were less likely to have a mild disease course and at increased risk for a secondary-progressive clinical type.

Plasma osteopontin levels in multiple sclerosis

Protective and therapeutic role for αB-crystallin in autoimmune demyelination

It is demonstrated that CRYAB is a potent negative regulator acting as a brake on several inflammatory pathways in both the immune system and central nervous system (CNS), and the immune response against a negative regulator of inflammation,CRYAB, in multiple sclerosis, would exacerbate inflammation and demyelination.

αB-Crystallin genotype has impact on the multiple sclerosis phenotype

Carriers of the rare allele CRYAB–650*C had an increased likelihood of a noninflammatory, neurodegenerative phenotype characterized by a relatively rapid, primary progressive clinical disease course in multiple sclerosis.